Cargando…
Treatment of major depressive disorders with generic duloxetine and paroxetine: a multi-centered, double-blind, double-dummy, randomized controlled clinical trial
BACKGROUND: This study is a pre-registration trial of generic duloxetine that was approved by the China Food and Drug Administration (approval number: 2006L01603). AIMS: Compare the treatment efficacy and safety of generic duloxetine to that of paroxetine in patients with major depressive disorders...
Autores principales: | WANG, Zhiyang, XU, Xiufeng, TAN, Qingrong, LI, Keqing, MA, Cui, XIE, Shiping, GAO, Chengge, WANG, Gang, LI, Huafang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Shanghai Municipal Bureau of Publishing
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4621288/ https://www.ncbi.nlm.nih.gov/pubmed/26549959 http://dx.doi.org/10.11919/j.issn.1002-0829.215064 |
Ejemplares similares
-
Efficacy and safety of generic escitalopram versus Lexapro in the treatment of major depression: a multicenter double-blinded randomized controlled trial
por: Yu, Yimin, et al.
Publicado: (2013) -
Double-blind, comparative study of milnacipran and paroxetine in Japanese patients with major depression
por: Kamijima, Kunitoshi, et al.
Publicado: (2013) -
Double-blind, comparative study of milnacipran and paroxetine in Japanese patients with major depression [Corrigendum]
Publicado: (2013) -
Clinical outcomes of patients with major depressive disorder treated with either duloxetine, escitalopram, fluoxetine, paroxetine, or sertraline
por: Huang, Jia, et al.
Publicado: (2018) -
Randomized, double‐blind, 6‐week non‐inferiority study of lurasidone and risperidone for the treatment of schizophrenia
por: Feng, Yuan, et al.
Publicado: (2020)